key: cord-0929189-4vmpiyw9
authors: Mellis, Alexandra M.; Meece, Jennifer K.; Halasa, Natasha B.; Chappell, James D.; McLean, Huong Q.; Grijalva, Carlos G.; Hanson, Kayla E.; Zhu, Yuwei; Kim, Ahra; Deyoe, Jessica; Ivacic, Lynn C.; Reed, Carrie; Talbot, H. Keipp; Rolfes, Melissa A.
title: SARS-CoV-2 virus dynamics in recently infected people – data from a household transmission study
date: 2022-05-05
journal: J Infect Dis
DOI: 10.1093/infdis/jiac180
sha: c1625fc7e0081ca76f9e64cfe5a2c2e3a420cc0b
doc_id: 929189
cord_uid: 4vmpiyw9

We used daily real-time reverse-transcription polymerase chain reaction (rRT-PCR) results from 67 cases of SARS-CoV-2 infection in a household transmission study, conducted April 2020--May 2021, to examine the trajectory of cycle threshold (Ct) values, an inverse correlate of viral RNA concentration. Ct values varied across RT-PCR platforms and by participant age. Specimens collected from children and adolescents had higher Ct values and adults aged ≥50 years showed lower Ct values than adults aged 18-49 years. Ct values were lower on days when participants reported experiencing symptoms, with the lowest Ct value occurring 2-6 days after symptom onset.

Cycle threshold (Ct) values, generated from real-time reverse-transcription polymerase 2 chain reaction (RT-PCR) assays, represent the minimum number of amplification cycles needed 3 to generate a signal for a specific target. Ct values are sometimes used as surrogate signals for 4 SARS-CoV-2 viral loads [1] , as they are inversely related to the amount of virus in the tested 5 specimen. Widespread availability of RT-PCR has led to comparisons of Ct values at the patient 6 and community levels to infer associations with illness severity and patient characteristics [2] . 7 However, Ct values can vary by assay, specimen type and quality, and time during the infection 8 course, especially complicating cross-sectional comparisons. Use of serial specimens collected 9 from one individual over the course of infection on the same assay can partially mitigate these 10 concerns, yet few investigations have used serial sampling to describe the natural history of 11 SARS-CoV-2 infection [3] [4] [5] or included specimens from the general population with 12 uncomplicated infection [6, 7] . 13 We described SARS-CoV-2 RT-PCR Ct values in newly infected individuals who 14 collected daily specimens as part of a prospective transmission study, and examined the impact 15 of age and symptoms on Ct value trajectories.

We conducted a household transmission study of SARS-CoV-2 in Tennessee and 18 Wisconsin [8, 9] between April 2020 and May 2021. Non-hospitalized individuals (index 19 participants) who had tested positive for SARS-CoV-2 by a provider-ordered nucleic acid 20 amplification test, and resided with at least one other individual, were recruited into the study 21 and consented and enrolled in the study, along with their household contacts, within 6 days of the 22 index participant's symptom onset. Study procedures included daily swabbing and symptom Table 1 ), for 14 consecutive days. All participants completed 1 demographic surveys and self-reported pre-existing conditions (asthma, chronic liver disease, 2 premature birth, cardiac conditions, diabetes, cancer, immunocompromising conditions, extreme 3 obesity, kidney disease, or pregnancy) and, after COVID-19 vaccines became available, 4 vaccination status (verified against health records and immunization information systems).

Anterior nasal swabs were self-/parent-collected by study participants. Swabs were either 6 placed in viral transport media (Remel MicroTest M4RT®, Lenexa, KS USA) and refrigerated 7 by participants for 7-10 days before transport, or placed in inactivating viral transport media 8 (Primestore®, Longhorn Vaccines & Diagnostics LLC, Bethesda, MD) and stored at room 9 temperature by participants for 1-3 days before transport to local laboratories for processing and 10 freezing at -80°C prior to testing. All specimens were tested by RT-PCR using either the CDC To examine trajectories of Ct values over the course of infection, we selected data from 3 household contacts who met the following criteria: individuals' first study specimen was 4 negative, they must have tested positive on ≥3 different days, and all specimens must have been 5 tested using the same assay (Supplemental Figure 1 ). Days of lowest Ct values were defined per 6 target (N1, N2, N, S, or ORF1ab). After exploring multiple model specifications (Supplementary 7 methods), we described Ct values over time using generalized additive models examining the 8 effect of age (representing age categorically, in groups 0-11, 12-17, or ≥50 years compared to 18-9 49 years), controlling for the target of each assay (which also differed by assay type), with a 10 random effect spline for repeated measurements and a smoothing thin plate spline for time since 11 first positive test. We also explored the effects of symptoms on each day of infection, controlling 12 for age; symptoms were considered binary (symptom present/absent) for both the primary results

(on impact of any symptom) and post-hoc analysis of individual symptoms (Supplemental Table   14 1).

A total of 577 household contacts from 302 households were enrolled in the parent study 17 April 2020-May 2021. Sixty-seven contacts from 50 households met our criteria for "incident Figure 1 ). Associations between other demographics and Ct values are presented Table 2 . A total of 544 specimens from incident cases were tested, including 1 1384 Ct values against SARS-CoV-2 targets. 2 The median observed number of positive days among incident cases was 10 (interquartile 3 range [IQR]: 8, 12 days), although 58% of participants' last specimen collected were still 4 positive for SARS-CoV-2 and participants were tested for a median of 10 days following first values were significantly lower on days incident cases reported fatigue, fever, aches, chills, 5 diarrhea, cough, chest tightness/pain, shortness of breath, wheezing, nasal congestion, runny 6 nose, sore throat, or headache (Supplemental Table 1 

To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value

Coronavirus 2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With 5

Viral dynamics of acute SARS-CoV-2 infection and 7 applications to diagnostic and public health strategies

Longitudinal analysis of SARS-CoV-2 vaccine 9 breakthrough infections reveal limited infectious virus shedding and restricted tissue distribution

Temporal dynamics in viral shedding and transmissibility of 12 COVID-19

Community transmission and viral load kinetics 14 of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the 15 UK: a prospective, longitudinal, cohort study

Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With 18 COVID-19 Symptom Onset and Severity

Household Transmission and Clinical Features 20 of SARS-CoV-2 Infections

Transmission of SARS-COV-2 infections in 22 households-Tennessee and Wisconsin

Surveillance and correlation of SARS-CoV-2 viral 25

RNA, antigen, virus isolation, and self-reported symptoms in a longitudinal study with daily 26 sampling

Committee Perspective: Caution Must Be Used in Interpreting the Cycle Threshold

Epidemiological Correlates of Polymerase Chain 31

Reaction Cycle Threshold Values in the Detection of Severe Acute Respiratory Syndrome 32

Coronavirus 2 (SARS-CoV-2)

Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus

Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19)

Comparison of Reverse-Transcription Polymerase 38

Chain Reaction Cycle Threshold Values From Respiratory Specimens in Symptomatic

Asymptomatic Children With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Clin 40

Infectious Diseases Society of America AfMP. IDSA and AMP joint statement on the use of 42

SARS-CoV-2 PCR cycle threshold (Ct) values for clinical decision-making